These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 23966104)

  • 1. The liver and the kidney: two critical organs influencing the atherothrombotic risk in metabolic syndrome.
    Carbone F; Montecucco F; Mach F; Pontremoli R; Viazzi F
    Thromb Haemost; 2013 Nov; 110(5):940-58. PubMed ID: 23966104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of chronic kidney disease in patients with non-alcoholic fatty liver disease: is there a link?
    Targher G; Chonchol M; Zoppini G; Abaterusso C; Bonora E
    J Hepatol; 2011 May; 54(5):1020-9. PubMed ID: 21145850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic syndrome, inflammation and atherothrombosis.
    Rohla M; Weiss TW
    Hamostaseologie; 2013; 33(4):283-94. PubMed ID: 23979637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonalcoholic fatty liver disease - A multisystem disease?
    Mikolasevic I; Milic S; Turk Wensveen T; Grgic I; Jakopcic I; Stimac D; Wensveen F; Orlic L
    World J Gastroenterol; 2016 Nov; 22(43):9488-9505. PubMed ID: 27920470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic syndrome, inflammation and atherosclerosis - the role of adipokines in health and in systemic inflammatory rheumatic diseases.
    Santos MJ; Fonseca JE
    Acta Reumatol Port; 2009; 34(4):590-8. PubMed ID: 20852572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between non-alcoholic fatty liver disease and kidney function: a communication between two organs that needs further exploration.
    Hamad AA; Khalil AA; Connolly V; Ahmed MH
    Arab J Gastroenterol; 2012 Dec; 13(4):161-5. PubMed ID: 23432982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation and characterization of a mouse model of the metabolic syndrome: apolipoprotein E and aromatase double knockout mice.
    Scott NJ; Cameron VA; Raudsepp S; Lewis LK; Simpson ER; Richards AM; Ellmers LJ
    Am J Physiol Endocrinol Metab; 2012 Mar; 302(5):E576-84. PubMed ID: 22185842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NAFLD in the absence of metabolic syndrome: different epidemiology, pathogenetic mechanisms, risk factors for disease progression?
    Yilmaz Y
    Semin Liver Dis; 2012 Feb; 32(1):14-21. PubMed ID: 22418884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum fatty acid patterns, insulin sensitivity and the metabolic syndrome in individuals with chronic kidney disease.
    Huang X; Sjögren P; Ärnlöv J; Cederholm T; Lind L; Stenvinkel P; Lindholm B; Risérus U; Carrero JJ
    J Intern Med; 2014 Jan; 275(1):71-83. PubMed ID: 24011327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease: an open question.
    Loria P; Lonardo A; Bellentani S; Day CP; Marchesini G; Carulli N
    Nutr Metab Cardiovasc Dis; 2007 Nov; 17(9):684-98. PubMed ID: 17560098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of non-alcoholic fatty liver disease in cardiovascular disease.
    Perseghin G
    Dig Dis; 2010; 28(1):210-3. PubMed ID: 20460913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The central role of the non alcoholic fatty liver disease in metabolic syndrome.
    Hurjui DM; Niţă O; Graur LI; Mihalache L; Popescu DS; Graur M
    Rev Med Chir Soc Med Nat Iasi; 2012; 116(2):425-31. PubMed ID: 23077931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic insulin resistance, metabolic syndrome and cardiovascular disease.
    Meshkani R; Adeli K
    Clin Biochem; 2009 Sep; 42(13-14):1331-46. PubMed ID: 19501581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin resistance and the metabolic syndrome are associated with arterial stiffness in patients with chronic kidney disease.
    Chan DT; Watts GF; Irish AB; Ooi EM; Dogra GK
    Am J Hypertens; 2013 Sep; 26(9):1155-61. PubMed ID: 23736110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-alcoholic fatty liver disease and cardiovascular disease: epidemiological, clinical and pathophysiological evidences.
    Del Ben M; Baratta F; Polimeni L; Angelico F
    Intern Emerg Med; 2012 Oct; 7 Suppl 3():S291-6. PubMed ID: 23073870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The epidemiology, pathogenesis and histopathology of fatty liver disease.
    Levene AP; Goldin RD
    Histopathology; 2012 Aug; 61(2):141-52. PubMed ID: 22372457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of non-alcoholic fatty liver disease on accelerated metabolic complications.
    Fan JG
    J Dig Dis; 2008 May; 9(2):63-7. PubMed ID: 18419637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Obesity and metabolic syndrome: potential benefit from specific nutritional components.
    Abete I; Goyenechea E; Zulet MA; Martínez JA
    Nutr Metab Cardiovasc Dis; 2011 Sep; 21 Suppl 2():B1-15. PubMed ID: 21764273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ectopic lipid accumulation: A potential cause for metabolic disturbances and a contributor to the alteration of kidney function.
    Guebre-Egziabher F; Alix PM; Koppe L; Pelletier CC; Kalbacher E; Fouque D; Soulage CO
    Biochimie; 2013 Nov; 95(11):1971-9. PubMed ID: 23896376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-alcoholic fatty liver disease, the metabolic syndrome and the risk of cardiovascular disease: the plot thickens.
    Targher G
    Diabet Med; 2007 Jan; 24(1):1-6. PubMed ID: 17227317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.